Clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease

• Published in: Scientific reports Vol. 11; no. 1; pp. 2884 - 12
• Main Authors: Kim, Kwang Min, Roh, Ji-Hye, Lee, Sangjin, Yoon, Jeong-Hyun
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03.02.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/4020; 692/699/1503/1607/2750; 692/700/459; Adult; Aged; Angiotensin; Antihypertensive Agents - administration & dosage; Body mass index; Case-Control Studies; Disease Progression; Fatty liver; Female; Fibrosis; Humanities and Social Sciences; Humans; Inflammation; Liver - drug effects; Liver - pathology; Liver diseases; Longitudinal Studies; Male; Middle Aged; multidisciplinary; Non-alcoholic Fatty Liver Disease - diagnosis; Non-alcoholic Fatty Liver Disease - etiology; Non-alcoholic Fatty Liver Disease - prevention & control; Obesity - complications; Obesity - drug therapy; Oxidative stress; Regression analysis; Renin; Renin-Angiotensin System - drug effects; Retrospective Studies; Risk Factors; Science; Science (multidisciplinary); Treatment Outcome; Young Adult

Recently, there has been an increasing interest in the therapeutic efficacy of RAS inhibitors (RASi) in patients with non-alcoholic fatty liver disease (NAFLD) because they may reduce oxidative stress, inflammatory markers, and enhanced fibrosis. An objective of this study was to investigate the rol...